CAR-T therapy for renal cell carcinoma gains fast track approval
Joining the strong number of cancer therapies being approved in 2023 is the CAR-T cell therapy from Invectys, the clinical-stage immuno-oncology company.
Invectys focuses on developing novel therapies for advanced cancers, and their latest therapy is no exception, using revolutionary technology to target HLA-G, an immune checkpoint and tumour-specific antigen that is often overlooked.
The HLA-G molecule is normally only expressed during pregnancy, with the purpose of protecting the foetus from the mother’s immune system. In cancer however, tumours can commandeer HLA-G to create a protected environment for them to thrive in, guarding against the natural immune system, allowing them to grow uninhibited.
The new product, IVS-3001, has been granted Fast Track Designation from the US FDA, for use in patients with HLA-G positive locally advanced or metastatic clear cell renal cell carcinoma (RCC) who have previously failed or are intolerant to pre-existing RCC therapies. The therapy is an autologous CAR-T therapy, forged from the patient’s own cells, modified to target HLA-G-bearing cells and will work to boost the body’s natural defences, enabling it to better fight against cancerous growth. The approval will aid in progressing cancer therapeutics, increasing options for patients, and ultimately leading to improved patient outcomes.
Fast Track designation is granted to revolutionary treatments aiming to fulfil an unmet need in serious medical conditions, in this case, HLA-G positive locally advanced or metastatic clear cell renal cell carcinoma that has been unresponsive to treatment. IVS-3001 is the first CAR-T therapy to be approved for RCC treatment.
The Fast Track designation for IVS-3001 was based on compelling data from the submission from Invectys to the Investigational New Drug Application (IND). Data is being collected from a Phase I/IIa clinical trial into solid tumours (NCT05672459) started in June 2023, with support from the MD Anderson and the Cell Therapy Manufacturing Centre (CTMC) for the development of the therapy.
“We are thrilled to receive the FDA’s Fast Track designation for IVS-3001,” commented Jake Kushner, CEO of Invectys. “This recognition further validates the potential of our CAR-T cell therapy in revolutionising cancer treatment for patients with solid tumours. The dedicated team at Invectys, as well as our partners, are committed to bringing this innovative therapy to the clinic and making a meaningful difference in the lives of cancer patients.”
Sources:
Pharmaceutical Technology. FDA fast-tracks Invectys’ CAR-T therapy for renal cell carcinoma. [Date Accessed 02/08/2023].
Invectys Cancer Immunotherapeutics. FDA Grants Fast Track designation to IVS-3001, a CAR-T Cell Therapy in the Treatment of Renal Cell Carcinoma. Date Accessed [02/08/2023].
Related News
-
News On Track at Pharmapack 2024 - The Track Sponsor interview: BD Pharmaceuticals
January 2024 brings both a new year and Europe’s leading packaging and drug delivery event. Bringing the world’s experts in pharmaceutical packaging together in Paris, France, Pharmapack 2024 brings exciting opportunities to learn and colla... -
News Patients vs Pharma – who will the Inflation Reduction Act affect the most?
The Inflation Reduction Act brought in by the Biden administration in 2022 aims to give better and more equitable access to healthcare in the USA. However, pharma companies are now concerned about the other potential costs of such legislation. -
News Roche breaks into the obesity drug market with the acquisition of Carmot Therapeutics
In a bid to diversify their therapeutic offerings, Roche takes over Carmot Therapeutics in $2.7 billion deal, with one obesity drug spearheading the venture into the field as they prep for a Phase II in-human trial. -
News Biden backs Cold-War measures to shore-up medical supply chains
In a recent strategy to combat rising inflation and the cost of living crisis, President Joe Biden has invoked a Cold War-era act to increase investment in a selection of medicines and supplies. -
News Women in Pharma: Delivering solutions for gender diversity
In our new monthly series, we interview women from across the pharmaceutical industry and supply chain to discuss the importance of gender diversity in healthcare, the workplace, and beyond. -
News CPHI Barcelona Speaker Interview – What the US FDA’s Quality Management Maturity Means for the Pharma Industry
At CPHI Barcelona (24–26 October, 2023), we spoke to Sireesha Yadlapalli, CEO of Pharmatech Associates, who gave a presentation on the implications of the US FDA’s Quality Management Maturity (QMM) Initiative, and spoke on the panel of the ... -
News CPHI Podcast Series: What does the changing US Pharma market mean for industry and patients alike?
In this week's episode of the CPHI Podcast Series Lucy Chard, Digital Editor for CPHI Online is joined by James Manser to discuss the political and market changes in the US pharma field. -
News Wegovy and weight-loss drugs driving demand for manufacturers that can fill syringes
Injectable weight-loss treatments are prompting contract manufacturers to invest and include fill-finish services into their service portfolios, in a bid to attract pharmaceutical giants developing drugs similar to Novo Nordisk's Wegovy.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance